BIMI International Medical Inc. Announces Fiscal Year 2021 Financial Results

Rhea-AI Summary

BIMI International Medical Inc. (NASDAQ: BIMI) reported its fiscal year 2021 results, showcasing a revenue increase to $27.08 million from $12.84 million in 2020, primarily from the Guanzan Group acquisition and additional hospitals. Despite this growth, the gross profit margin declined to 17% from 19%, mainly due to lower margin products in wholesale pharmaceuticals. Operating expenses surged by 99% to $12.70 million, significantly impacting net loss, which expanded to $34.92 million from $1.88 million. Cash reserves were $4.80 million, with negative working capital of $932,493.

Positive

• Revenue increased by $14.23 million, attributed to acquisitions.
• Expansion of service offerings with a focus on a cloud-based telehealth platform.

Negative

• Net loss surged to $34.92 million from $1.88 million in 2020.
• Gross profit margin decreased from 19% to 17% due to product mix changes.
• Operating expenses rose by 99% to $12.70 million.
• Significant impairment charges totaling $26.80 million related to goodwill.

NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced its financial results for the fiscal year ended December 31, 2021.

Revenues for the years ended December 31, 2021 and 2020 were $27,079,795 and $12,844,902, respectively. The increase of $14,234,893 is mainly due to the full year of revenues of the Guanzan Group, which was acquired in March 2020 and acquisitions of the Guoyitang, Qiangsheng, Eurasia and Minkang hospitals in 2021.

For the year ended December 31, 2021, the revenues of the retail pharmacies, wholesale medical devices, wholesale pharmaceuticals and medical services were $316,647, $3,445,107, $16,905,498 and $6,398,379, respectively. For the year ended December 31, 2020, the revenues of the retail pharmacies, wholesale medical devices and wholesale pharmaceuticals were $84,087, $3,059,462 and $ 9,701,353, respectively.

For the year ended December 31, 2021 the Company had a gross profit margin of 17% compared with gross profit margin of 19% for the year ended December 31, 2020. The decrease in the gross profit margin in 2021 was mainly due to the decrease in the wholesale pharmaceuticals segment from 19.1% in 2020 to 2.7% in 2021 caused by a change in the product mix to products with a lower gross profit margin.

The gross profit margin of the retail pharmacies, wholesale medical devices, wholesale pharmaceuticals and medical services segments for the year ended December 31, 2021 were 36.8%, 12.0%, 2.7% and 57.3%, respectively. The gross profit margin of the retail pharmacies, wholesale medical devices, wholesale pharmaceuticals segments for the year ended December 31, 2020 were 16.6%, 18.9% and 19.1%, respectively.

Operating expenses were $12,703,345 for the year ended December 31, 2021 compared to $6,255,098 for the year ended December 31, 2020, an increase of $6,207,182, or 99%. Operating expenses for the year ended December 31, 2021 consisted mainly of salary and employee benefits in the amount of $2,273,313, amortization of the convertible notes in the amount of $1,977,401, selling expenses in the amount of $3,180,252, depreciation and amortization expense of $244,116, audit fees of $543,299, and other professional service fees in the amount of $906,852.

For the year ended December 31, 2021, the Company reported other expense of $26,795,423 relating to the impairment of goodwill compared to other income of $460,552 for the year ended December 31, 2020. For the year ended December 31, 2021, the Guanzan Group incurred an impairment charge of $ 1,923,071. Such impairment charge was recorded after the completion of an earn-out period. Guoyitang incurred an impairment charge of $7,154,393, primarily because the 2021 performance targets set forth in Guoyitang’s acquisition agreement were not met as a result of the pandemic and lockdowns. Zhongshan hospital incurred an impairment charge of $9,134,277, primarily because its 2021 performance targets were not met as a result of the pandemic and lockdowns. The Qiangsheng, Eurasia and Minkang hospitals incurred an impairment charge of $7,916,431, primarily because their 2021 performance targets were not met as a result of the pandemic and lockdowns.

The Company reported a net loss of $34,921,745 for the year ended December 31, 2021, compared to a net loss of $1,877,925 for the year ended December 31, 2020, an increase of $33,043,820.

As of December 31, 2021, the Company had cash of $4,797,849 and negative working capital of $932,493 as compared to cash of $135,309 and working capital of $9,619,274 on December 31, 2020.

“Our newly-acquired businesses were severely impacted by COVID-19 and local lockdowns which caused the significant impairment charges in 2021. We believe the decision for the impairment charges was a responsible action that will benefit our shareholders in the long term. As part of our efforts to improve operations and increase shareholder value, we plan to enhance our smart hospital brand by providing more technical and management support, such as a cloud-based telehealth platform and a medical talent pool program to our existing hospitals, and use our established brand to attract more hospitals that may bring new opportunities and profits to our Company,” said Mr. Tiewei Song, Chief Executive Officer and President of BIMI International Medical Inc.

About BIMI International Medical Inc.

BIMI International Medical Inc. was founded in 2006. The Company is now exclusively a healthcare products and services provider, offering a broad range of healthcare products and related services and operates five private hospitals in China. For more information, please visit www.usbimi.com.

Safe Harbor Statement

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of COVID-19, the demand for the Company’s products and services in the People’s Republic of China, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission.

IR Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BIMI@dgipl.com

 

 

BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

		December 31				December 31
		2021				2020
ASSETS
CURRENT ASSETS
Cash		$	4,797,849			$	135,309
Accounts receivable, net			7,005,442				6,686,552
Advances to suppliers			3,163,836				2,693,325
Amount due from related parties			622,554				-
Inventories, net			2,639,883				735,351
Prepayments and other receivables			2,930,083				14,880,526
Operating lease-right of use assets			-				53,425
Total current assets			21,159,647				25,184,488
NON-CURRENT ASSETS
Deferred tax assets			207,549				193,211
Property, plant and equipment, net			3,521,401				910,208
Intangible assets, net			18,039				-
Operating lease-right of use assets			4,845,509				-
Goodwill			8,376,217				6,914,232
Total non-current assets			16,968,715				8,017,651
TOTAL ASSETS		$	38,128,362			$	33,202,139
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Short-term loans		$	1,799,394			$	904,228
Long-term loans due within one year			369,187				34,201
Convertible promissory notes, net			5,211,160				3,328,447
Accounts payable, trade			7,339,210				5,852,050
Advances from customers			1,943,028				194,086
Amount due to related parties			730,285				226,514
Taxes payable			662,777				773,649
Other payables and accrued liabilities			3,082,917				4,228,976
Lease liability-current			954,182				23,063
Total current liabilities			22,092,140				15,565,214
NON-CURRENT LIABILITIES
Lease liability-non current			4,161,789				22,457
Long-term loans - non-current			538,006				720,997
Total non-current liabilities			4,699,795				743,454
TOTAL LIABILITIES			26,791,935				16,308,668
EQUITY
Common stock, $0.001 par value; 200,000,000 shares authorized; 8,502,222 and 2,650,917 shares issued and outstanding as of December 31, 2021 and 2020, respectively *			8,502				2,651
Additional paid-in capital			55,220,130				26,355,523
Statutory reserves			2,263,857				2,263,857
Accumulated deficit			(47,900,929	)			(12,914,973	)
Accumulated other comprehensive income			1,601,870				1,003,392
Total BIMI International Medical Inc.’s equity			11,193,430				16,710,450
NON-CONTROLLING INTERESTS			142,997				183,021
Total equity			11,336,427				16,893,471
Total liabilities and equity		$	38,128,362			$	33,202,139

*

Retrospectively restated due to five for one reverse stock split, see Note 24

The accompanying notes are an integral part of the consolidated financial statements

BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE GAIN/LOSS

		For the Years Ended December 31
		2021				2020
REVENUES			27,079,795				12,844,902
COST OF REVENUES			22,483,404				10,402,085
GROSS PROFIT			4,596,391				2,442,817
OPERATING EXPENSES:
Sales and marketing			3,180,252				783,134
General and administrative			9,523,093				5,471,964
Total operating expenses			12,703,345				6,255,098
LOSS FROM OPERATIONS			(8,106,954	)			(3,812,281	)
OTHER INCOME (EXPENSE)
Interest income			3,101				304
Interest expense			(351,066	)			(84,913	)
Exchange gains			24,967				547,114
Impairment loss of goodwill			(26,128,171	)			-
Other expense			(344,254	)			(1,953	)
Total other income (expense), net			(26,795,423	)			460,552
LOSS BEFORE INCOME TAXES			(34,902,377	)			(3,351,729	)
PROVISION FOR INCOME TAXES			19,368				434,306
NET LOSS FROM CONTINUING OPERATIONS			(34,921,745	)			(3,786,035	)
DISCONTINUED OPERATIONS
Income/(loss) from operations of discontinued operations			-				1,908,110
NET LOSS			(34,921,745	)			(1,877,925	)
Less: net income attributable to non-controlling interest			64,211				119,158
NET LOSS ATTRIBUTABLE TO BIMI INTERATIONAL MEDICAL INC.		$	(34,985,956	)		$	(1,997,083	)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment			598,478				(941,957	)
TOTAL COMPREHENSIVE LOSS			(34,323,267	)			(2,819,882	)
Less: comprehensive loss attributable to non-controlling interests			(26,056	)			(17,113	)
COMPREHENSIVE LOSS ATTRIBUTABLE TO BIMI INTERNATIONAL MEDICAL INC.		$	(34,297,211	)		$	(2,802,769	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES
Basic and diluted			5,362,927				2,134,562
LOSS PER SHARE
Continuing operation-Basic and diluted		$	(6.51	)		$	(1.77	)
Discontinued operation-Basic and diluted		$	-			$	0.89
Basic and diluted		$	(6.51	)		$	(0.88	)

BIMI INTERNATIONAL MEDICAL, INC. AND ITS SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

		For the Years Ended December 31,
		2021				2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(34,921,745	)		$	(3,786,035	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization			244,116				56,041
Impairment loss of Goodwill			26,128,171				-
Inventories impairment reserve			93,884				9,294
Allowance for doubtful accounts			(53,698	)			146,977
Amortization of discount of convertible promissory notes			554,292				2,091,927
Change in operating assets and liabilities
Accounts receivable			685,426				(4,997,548	)
Advances to suppliers			(457,841	)			(1,470,339	)
Inventories			(1,434,531	)			205,580
Prepayments and other receivables			9,812,297				(1,021,703	)
Operating lease-right of use assets			(976,372	)			(53,425	)
Accounts payable, trade			(453,738	)			4,548,651
Advances from customers			1,702,762				(1,156,040	)
Operating lease liabilities			915,004				45,520
Taxes payable			(495,987	)			429,006
Other payables and accrued liabilities			(2,617,765	)			590,979
Net cash used in operating activities from continuing operations			(1,275,725	)			(4,361,115	)
Net cash provided by operating activities from discontinued operations			-				843,382
Net cash used in operating activities			(1,275,725	)			(3,517,733	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash received from acquisition of Guanzan Group			-				95,220
Cash received from acquisition of subsidiaries			189,896				-
Payment for the acquisition of Qiangsheng, Eurasia and Mingkang Hospitals			(3,136,910	)			-
Payment for the acquisition of Guoyitang and Zhongshan			-				(9,195,543	)
Deposit for the acquisition of Cogmer			3,065,181				(3,065,181	)
Purchase of property, plant, and equipment			(814,684	)			(258,961	)
Net cash used in investing activities from continuing operations			(696,517	)			(12,424,465	)
Net cash provided by investing activities from discontinued operations			-				11,700,000
Net cash (used in) investing activities			(696,517	)			(724,465	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term loan			-				65,302
Proceeds from long-term loan			151,995				534,201
Net proceeds from issuance of convertible promissory notes			6,500,000				3,457,325
Repayment of short-term loans			(33,273	)			(216,462	)
Amount financed from (to) related parties			(478,183	)			148,700
Net cash provided by financing activities from continuing operations			6,140,539				3,989,066
Net cash provided by financing activities from discontinued operations			-				-
Net cash provided by investing activities			6,140,539				3,989,066
EFFECT OF EXCHANGE RATE ON CASH			494,243				386,840
INCREASE IN CASH			4,662,540				133,708
CASH AND CASH EQUIVALENTS, beginning of period			135,309				1,601
CASH AND CASH EQUIVALENTS, end of period		$	4,797,849			$	135,309
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income tax		$	444,633			$	45,178
Cash paid for interest expense, net of capitalized interest		$	163,883			$	101,417
NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES
Issuance of shares of Common stock for the equity acquisition of Chongqing Guanzan Technology Co., Ltd.		$	3,818,000			$	4,537,000
Issuance of shares of Common stock for equity acquisition of Zhongshan Chaohu Hospital		$	3,480,000			$	-
Issuance of shares of Common stock for equity acquisition of Guoyitang Hospital		$	3,820,000			$	-
Issuance of shares of Common stock for equity acquisition of Minkang, Qiangsheng and Eurasia hospitals		$	5,930,619			$	-
Issuance of shares of Common stock for equity acquisition of Zhuoda		$	1,498,200				-
Issuance of shares of Common stock for payment of improvements to offices		$	696,896				-
Goodwill recognized from equity acquisition of Zhongshan Chaohu Hospital		$	10,443,494			$	-
Goodwill recognized from equity acquisition of Guoyitang Hospital		$	7,154,393			$	-
Goodwill recognized from equity acquisition of Minkang, Qiangsheng and Eurasia hospitals		$	9,067,529			$	-
Goodwill recognized from equity acquisition of Zhuoda		$	924,740
Goodwill recognized from equity acquisition of Guanzan Group		$	6,914,212			$	6,914,212
Outstanding payment for equity acquisition of Zhuoda		$	4,800,000			$	-
Outstanding payment for equity acquisition of Guanzan Group		$	-			$	3,065,181
Common stock to be issued upon conversion of convertible promissory notes		$	5,400,000			$	-

FAQ

What were BIMI's total revenues for the year ended December 31, 2021?

BIMI reported total revenues of $27,079,795 for the year ended December 31, 2021.

How did BIMI's net loss change from 2020 to 2021?

BIMI's net loss increased significantly to $34,921,745 in 2021 from $1,877,925 in 2020.

What were the primary reasons for the increase in BIMI's operating expenses in 2021?

Operating expenses rose by 99% due to higher costs such as salaries, amortization, and selling expenses.

What impacts did COVID-19 have on BIMI's financial results?

COVID-19 caused significant impairment charges and affected the performance targets of several acquired hospitals.

What is BIMI's cash position as of December 31, 2021?

As of December 31, 2021, BIMI reported cash reserves of $4,797,849.